Join

Compare · CRDL vs SGEN

CRDL vs SGEN

Side-by-side comparison of Cardiol Therapeutics Inc. (CRDL) and Seagen Inc. (SGEN): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both CRDL and SGEN operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
  • SGEN is the larger of the two at $23.34B, about 187.4x CRDL ($124.5M).
  • CRDL has hit the wire 1 time in the past 4 weeks while SGEN has been quiet.
  • SGEN has more recent analyst coverage (25 ratings vs 6 for CRDL).
MetricCRDLSGEN
Company
Cardiol Therapeutics Inc.
Seagen Inc.
Price
$1.08+0.46%
$228.86-0.01%
Market cap
$124.5M
$23.34B
1M return
-18.11%
-
1Y return
-23.05%
-
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ
NASDAQ
IPO
2001
News (4w)
1
0
Recent ratings
6
25
CRDL

Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc., a clinical-stage biotechnology company, focuses on the research and development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, an ultra-pure and high concentration cannabidiol oral formulation for the treatment of in hospitalized COVID-19 patients with a prior history of risk factors for CVD; and has completed phase I clinical trials for the treatment of acute myocarditis and other inflammatory heart disease. The company is also developing a proprietary subcutaneous formulation of cannabidiol to achieve higher bioavailability for the treatment chronic heart failure. In addition, it develops proprietary nanotechnology to enable the distribution of water insoluble drugs within the blood circulation, enhance pharmacokinetics, and facilitate drug accumulation in the failing heart. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.

SGEN

Seagen Inc.

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops Tisotumab Vedotin for metastatic cervical cancer and other solid tumors; ladiratuzumab vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and SpringWorks Therapeutics, Inc. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

Latest CRDL

Latest SGEN